These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The role of growth factors in degenerative joint disorders. Moskowitz RW; Boja B; Denko CW J Rheumatol Suppl; 1991 Feb; 27():147-8. PubMed ID: 2027117 [TBL] [Abstract][Full Text] [Related]
8. Exercise and the growth hormone-insulin-like growth factor axis. Frystyk J Med Sci Sports Exerc; 2010 Jan; 42(1):58-66. PubMed ID: 20010129 [TBL] [Abstract][Full Text] [Related]
9. Age-related changes in serum growth hormone, insulin-like growth factor-1 and somatostatin in system lupus erythematosus. Denko CW; Malemud CJ BMC Musculoskelet Disord; 2004 Oct; 5(1):37. PubMed ID: 15496230 [TBL] [Abstract][Full Text] [Related]
10. Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. Luque RM; Gahete MD; Valentine RJ; Kineman RD J Mol Endocrinol; 2006 Aug; 37(1):25-38. PubMed ID: 16901921 [TBL] [Abstract][Full Text] [Related]
11. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I. Sjögren K; Jansson JO; Isaksson OG; Ohlsson C Minerva Endocrinol; 2002 Dec; 27(4):299-311. PubMed ID: 12511852 [TBL] [Abstract][Full Text] [Related]
13. The role of neuroendocrine system in the pathogenesis of rheumatic diseases (minireview). Imrich R Endocr Regul; 2002 Jun; 36(2):95-106. PubMed ID: 12207559 [TBL] [Abstract][Full Text] [Related]
14. Intra-erythrocyte deposition of growth hormone in rheumatic diseases. Denko CW; Boja B; Malemud CJ Rheumatol Int; 2003 Jan; 23(1):11-4. PubMed ID: 12548436 [TBL] [Abstract][Full Text] [Related]
15. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [TBL] [Abstract][Full Text] [Related]
16. Growth factors, insulin-like growth factor-1 and growth hormone, in synovial fluid and serum of patients with rheumatic disorders. Denko CW; Boja B; Moskowitz RW Osteoarthritis Cartilage; 1996 Dec; 4(4):245-9. PubMed ID: 11048621 [TBL] [Abstract][Full Text] [Related]
17. Differential responses of the growth hormone axis in two rat models of streptozotocin-induced insulinopenic diabetes. Kim E; Sohn S; Lee M; Jung J; Kineman RD; Park S J Endocrinol; 2006 Feb; 188(2):263-70. PubMed ID: 16461552 [TBL] [Abstract][Full Text] [Related]
18. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Wiesli P; Zwimpfer C; Zapf J; Schmid C Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465 [TBL] [Abstract][Full Text] [Related]
19. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Hilal G; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D Arthritis Rheum; 1999 Oct; 42(10):2112-22. PubMed ID: 10524682 [TBL] [Abstract][Full Text] [Related]
20. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Cheema GS; Roschke V; Hilbert DM; Stohl W Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]